Search clinical trials for: GSK2269557

Total 10 results

GlaxoSmithKline

Completed

Absorption & Elimination of Radiolabelled GSK2269557

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

Study to Investigate Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Single & Repeat Doses of GSK2269557

Asthma

United Kingdom
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Dose-Response Relationship of Multiple Doses of GSK2269557 Administered as a Dry Powder to Chronic Obstructive Pulmonary Disease (COPD) Patients

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

Safety, Tolerability and Pharmacokinetics (PK) Study of GSK2269557 in Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Repeat Doses of the Dry Powder Formulation of GSK2269557 in Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United Kingdom
GlaxoSmithKline

Completed

A Study to Investigate the Efficacy, Safety, and Tolerability of Repeat Doses of Inhaled GSK2269557 in Adults With Persistent, Uncontrolled Asthma

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

An Efficacy Study of GSK2269557 Added to Standard Care in Subjects With an Acute Exacerbation of Chronic Obstructive Pulmonary Disease

Pulmonary Disease, Chronic Obstructive

Romania, Russian Federation, Belgium, Denmark, Netherlands
GlaxoSmithKline

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of GSK2269557 to Japanese Healthy Subjects

Pulmonary Disease, Chronic Obstructive

Japan
GlaxoSmithKline

Completed

A Study to Evaluate the Safety, Efficacy and Changes in Induced Sputum and Blood Biomarkers Following Daily Repeat Doses of Inhaled GSK2269557 in Chronic Obstructive Pulmonary Disease (COPD) Subjects With Acute Exacerbation

Pulmonary Disease, Chronic Obstructive

Canada, Denmark
GlaxoSmithKline

Completed

Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK2269557 Administered Via the ELLIPTA Dry Powder Inhaler to Healthy Subjects

Pulmonary Disease, Chronic Obstructive

United States

3

Subscribe